
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Abd Tahrani is a UK National Institute for Health Research Clinician Scientist and Honorary Consultant Physician at the University of Birmingham and Heart of England NHS Foundation Trust, Birmingham, UK. He has undertaken research into the pathogenesis of diabetes-related microvascular complications, the pathogenesis and management of obesity, the metabolic consequences of sleep-related disorders and the pharmacology of diabetes.
Anthony Barnett is Emeritus Professor of Medicine and Honorary Consultant Physician at the University of Birmingham and Heart of England NHS Foundation Trust, Birmingham, UK. He has undertaken extensive research into the genetics and pathogenesis of type 1 and type 2 diabetes mellitus and associated complications, along with Health Service-related research in ethnic minority groups and the development and use of glucose-lowering therapies. He has been a regular adviser to both the UK National Institute for Health and Care Excellence and the European Medicines Agency.
Clifford Bailey is Professor of Clinical Science at Aston University, Birmingham, UK, and has undertaken extensive research on the pathogenesis of type 2 diabetes mellitus and the development of glucose-lowering therapies. He is an editor of Diabetes and Vascular Disease Research, and has served as an expert witness to medicines regulatory agencies.
Nature Reviews Endocrinology volume 12, pages 566592 (2016)
Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to
Continue
reading